Skip to content

Intercept Pharmaceuticals, Inc.: 10-Q filed 2013-11-14

What Intercept Pharmaceuticals, Inc. reported in its quarterly report filed 2013-11-14 (fiscal Q3 2013): 26 published measures, 78 facts as tagged in accession 0001144204-13-061223.

This filing

Form
10-Q (quarterly report)
Filed
2013-11-14
Fiscal period
fiscal Q3 2013
Accession
0001144204-13-061223 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Intercept Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-09-30158,891,289USD
At 2012-12-31112,178,597USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-09-3067,928,873USD
At 2012-12-3146,266,732USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-09-3090,962,416USD
At 2012-12-3165,911,865USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-09-3033,492,017USD
At 2012-12-3145,511,641USD
At 2012-09-3035,971,386USD
At 2011-12-3117,707,476USD
At 2002-09-030USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-31,737,073USD92
2013-01-01 to 2013-09-30-55,424,138USD273
2002-09-04 to 2013-09-30-173,607,488USD4045
2012-07-01 to 2012-09-30-5,186,988USD92
2012-01-01 to 2012-09-30-12,952,668USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-09-30-17,581,104USD273
2002-09-04 to 2013-09-30-85,226,157USD4045
2012-01-01 to 2012-09-30-11,457,233USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-01-01 to 2013-09-30121,205USD273
2002-09-04 to 2013-09-301,518,443USD4045
2012-01-01 to 2012-09-3024,112USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-09-3065,477,668USD273
2002-09-04 to 2013-09-30245,672,865USD4045
2012-01-01 to 2012-09-3029,632,089USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-09-30-59,916,188USD273
2002-09-04 to 2013-09-30-126,762,958USD4045
2012-01-01 to 2012-09-3096,287USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-09-30190,673USD
At 2012-12-31148,838USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-09-306,478,346USD273
2002-09-04 to 2013-09-3016,256,216USD4045
2012-01-01 to 2012-09-301,251,579USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-09-30158,354,005USD
At 2012-12-31111,778,219USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-09-307,511,070USD
At 2012-12-3112,964,054USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-09-301,384,000USD
At 2012-12-311,180,000USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-07-01 to 2013-09-308,392,628USD92
2013-01-01 to 2013-09-3018,358,155USD273
2002-09-04 to 2013-09-3089,792,846USD4045
2012-07-01 to 2012-09-303,318,310USD92
2012-01-01 to 2012-09-3011,395,924USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-09-3019,300,957shares
At 2012-12-3116,526,885shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-09-30264,519,497USD
At 2012-12-31184,100,139USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2013-09-3031,106USD
At 2012-12-31-21,451USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2013-09-30934,000USD
At 2012-12-31813,000USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2013-09-30743,000USD
At 2012-12-31664,000USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2013-09-301,601,213USD
At 2012-12-311,584,308USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-31,737,073USD92
2013-01-01 to 2013-09-30-55,424,138USD273
2002-09-04 to 2013-09-30-184,551,622USD4045
2012-07-01 to 2012-09-30-6,186,988USD92
2012-01-01 to 2012-09-30-15,452,668USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-07-01 to 2013-09-303,115,095USD92
2013-01-01 to 2013-09-308,402,454USD273
2002-09-04 to 2013-09-3038,000,536USD4045
2012-07-01 to 2012-09-30991,062USD92
2012-01-01 to 2012-09-302,994,121USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2013-01-01 to 2013-09-3079,370USD273
2002-09-04 to 2013-09-302,446,039USD4045
2012-01-01 to 2012-09-30178,469USD274

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-20,634,757USD92
2013-01-01 to 2013-09-30-29,879,748USD273
2002-09-04 to 2013-09-30-51,281,560USD4045
2012-07-01 to 2012-09-30-1,400,807USD92
2012-01-01 to 2012-09-30-603,323USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-01-01 to 2013-09-3061,169,317USD273
2002-09-04 to 2013-09-30233,646,479USD4045
2012-10-01 to 2012-10-3178,700,000USD31
2012-01-01 to 2012-09-3029,713,851USD274

Inspect the source

Entity
Intercept Pharmaceuticals, Inc. / CIK 0001270073
Captured
SEC response SHA-256
189a532afeabeae693af9861cccd21096e4f8b32f84ccd47de7c30ab97054fba

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001270073.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))